Please login to the form below

Not currently logged in
Email:
Password:

Martin Shkreli

This page shows the latest Martin Shkreli news and features for those working in and with pharma, biotech and healthcare.

Theranos and its CEO settle 'massive fraud' charges

Theranos and its CEO settle 'massive fraud' charges

A separate case will proceed again Balwani. Holmes will, however, avoid jail time, unlike former Turing CEO Martin Shkreli, who was arrested in 2015 by the FBI on securities fraud charges

Latest news

  • Connecting the dots Connecting the dots

    In a world like this, how many Marathons, Valeants and Martin Shkreli’s do you think there would be?

  • Making a list and checking it twice… Making a list and checking it twice…

    Let's start with an obvious one: prices and price increases. The hangover effect of Martin Shkreli and Valeant Pharmaceuticals in 2015 continued to haunt the industry along with new dramas

  • EpiDemic EpiDemic

    And the next egregious drug-pricing headline is yet to come. But like Valeant and Martin Shkreli before it, the EpiPen narrative teaches us some important lessons.

  • Retrophin rockets away as rare disease trial hits targets Retrophin rockets away as rare disease trial hits targets

    Last year, Retrophin was indirectly caught up in the scandal surrounding its founder Martin Shkreli - who was eventually fired by the board and faced allegations of using company stock to pay ... Sparsentan was brought into Retrophin's pipeline by

  • Post-Shkreli KaloBios pledges transparent pricing Post-Shkreli KaloBios pledges transparent pricing

    Post-Shkreli KaloBios pledges transparent pricing. Will seek input from “ key stakeholders” and share reasoning behind pricing of drugs. ... KaloBios became embroiled in the furore surrounding the pricing antics of Martin Shkreli last year -

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    treat toxoplasmosis, being given a 5, 000% price increase ($13.50 per pill to $750), to “ fund future research into the disease” and the subsequent backlash against its CEO Martin Shkreli ... in net cash to fund its near-term development needs and

  • Pharma deals during February 2014 Pharma deals during February 2014

    According to Martin Shkreli, founder and CEO: “ We also intend to move quickly to pursue FDA approval of Chenodal for CTX.".

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics